Pharmacovigilance is the science and the set of activities relating to the detection, collection, assessment, understanding, and prevention of adverse drug reactions (ADRs) and other medicine-related problems. The overarching objective is to ensure medicinal product safety throughout the entire product life cycle—from early clinical development and marketing authorisation through to the post-market phase. In the EU, the legal basis is primarily Implementing Regulation (EU) No 520/2012 and Directive 2010/84/EU, which fundamentally redesigned the pharmacovigilance system in Europe.
Regulatory framework in the EU
In the European Union, the European Medicines Agency (EMA), together with the national competent authorities—in Germany, the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institut (PEI)—is responsible for monitoring medicinal product safety. The European pharmacovigilance system is based on the EudraVigilance database, in which reports of suspected adverse drug reactions (Individual Case Safety Reports, ICSRs) are centrally recorded. Marketing authorisation holders are required to report suspected unexpected serious adverse reactions (SUSARs) within strict timelines: 7 days for life-threatening reactions and 15 days for other serious cases. These reporting obligations apply both to clinical trials and to authorised medicinal products on the market. Consistent compliance with these timelines is subject to regular inspections by national authorities and the EMA and is a frequently audited area in GVP audits.
Core tasks and tools
Practical pharmacovigilance covers a broad range of activities. These include the collection and evaluation of spontaneous reports from clinical practice, systematic literature monitoring, signal management, and the preparation of regulatory reports. Key documents include the Periodic Safety Update Report (PSUR) or Periodic Benefit-Risk Evaluation Report (PBRER), which periodically assesses the benefit–risk balance of an authorised medicinal product, as well as the Risk Management Plan (RMP), which defines preventive and risk-minimisation measures for each authorised medicinal product. In clinical trials, safety data are summarised in the Development Safety Update Report (DSUR).
Pharmacovigilance in clinical trials
Strict pharmacovigilance requirements apply as early as during clinical development. In accordance with ICH E6(R3) and EU Regulation 536/2014 (CTR), serious adverse events (SAEs) must be reported by the Principal Investigator to the sponsor without delay. The Data Safety Monitoring Board (DSMB) continuously monitors safety data from ongoing studies and may recommend terminating a study if critical safety signals arise. Responsibilities between the sponsor, CRO, and investigational sites must be clearly defined in written agreements. The Qualified Person for Pharmacovigilance (QPPV) is the responsible person on the marketing authorisation holder’s side.
Signal management and risk assessment
Signal management refers to the structured process of identifying, validating, and assessing potentially safety-relevant information from safety databases, scientific literature, and other sources. The EMA guidelines on signal detection and assessment (GVP Module IX) define minimum standards for data mining in EudraVigilance. Detected signals undergo a multi-step assessment process: following initial detection, medical and scientific experts review causality and clinical relevance. Where safety signals are confirmed, authorities may mandate measures ranging from changes to product information and Direct Healthcare Professional Communications (DHPCs) to market withdrawal. Pharmacovigilance is therefore a key mechanism for protecting public health and for the continuous benefit–risk assessment of medicinal products. For companies in contract research and regulatory affairs, a solid understanding of pharmacovigilance requirements is essential, as non-compliance can lead to significant sanctions and marketing authorisation risks.
Frequently Asked Questions
What is the difference between an ADR and an SAE?
An adverse drug reaction (ADR) is a harmful and unintended response to a medicinal product. A serious adverse event (SAE) is a broader concept that includes any medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, or leads to persistent damage—regardless of whether there is a causal relationship with the medicinal product. A SUSAR is an SAE that is unexpected and suspected to be caused by the investigational medicinal product.
Who is responsible for the pharmacovigilance of a medicinal product?
The marketing authorisation holder (MAH) bears primary responsibility for the pharmacovigilance system for its medicinal product. It is required to appoint a Qualified Person for Pharmacovigilance (QPPV), maintain a Pharmacovigilance System Master File (PSMF), and operate a functional pharmacovigilance system. In clinical trials, responsibility lies with the sponsor, which may delegate tasks to CROs without transferring responsibility.
What is EudraVigilance?
EudraVigilance is the European data-processing network and management system for reporting and evaluating suspected adverse drug reactions. It is operated by the EMA and serves as the central repository for ICSRs from clinical trials and post-marketing surveillance in the European Economic Area. Marketing authorisation holders, clinical trial sponsors, and national authorities are required to report to EudraVigilance.
Regulatory References
- Directive 2010/84/EU: Amendment of Directive 2001/83/EC with regard to pharmacovigilance
- Implementing Regulation (EU) No 520/2012: Pharmacovigilance activities pursuant to Regulation (EC) No 726/2004
- EU Regulation No 536/2014 (CTR), Chapter VII: Safety reporting in clinical trials
- ICH E2A: Clinical Safety Data Management – Definitions and Standards for Expedited Reporting
- ICH E6(R3): Good Clinical Practice, section on safety reporting
- EMA Guideline on Good Pharmacovigilance Practices (GVP), Modules I–XVI